Tomasz Zal joined Immatics in May 2022 to head the Immunology Department at Immatics US.
Tomasz has been exploring T cell immunology for most of his professional life, from molecular mechanisms to clinical applications. At the National Institute for Medical Research, London, U.K., he studied T cell tolerance and activation, followed by T cell Receptor (TCR) interactions at The Scripps Research Institute, La Jolla, CA, USA. As a Faculty at MD Anderson Cancer Center, he led research in T cell surveillance and immuno-oncology across solid and hematological tumor types, and co-directed immunology graduate program. Before joining Immatics, Tomasz was the senior director of immunology R&D at Elephas Corp to predict patient responses to immune therapies.
Tomasz Zal holds a Doctor of Philosophy degree in molecular biology from Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of Polish Academy of Sciences and Master of Science degree from Wroclaw University of Science and Technology.